PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy.

Sasikumar, Pottayil G; Sudarshan, Naremaddepalli S; Adurthi, Srinivas; Ramachandra, Raghuveer K; Samiulla, Dodderi S; Lakshminarasimhan, Anirudha; Ramanathan, Anuradha; Chandrasekhar, Talapaneni; Dhudashiya, Amit A; Talapati, Sumalatha R; Gowda, Nagesh; Palakolanu, Sreenivasulareddy; Mani, Jiju; Srinivasrao, Bandi; Joseph, David; Kumar, Nigam; Nair, Rashmi; Atreya, Hanudatta S; Gowda, Nagaraj; Ramachandra, Murali

Sasikumar, Pottayil G; Sudarshan, Naremaddepalli S; Adurthi, Srinivas; Ramachandra, Raghuveer K; Samiulla, Dodderi S; Lakshminarasimhan, Anirudha; Ramanathan, Anuradha; Chandrasekhar, Talapaneni; Dhudashiya, Amit A; Talapati, Sumalatha R; Gowda, Nagesh; Palakolanu, Sreenivasulareddy; Mani, Jiju; Srinivasrao, Bandi; Joseph, David; Kumar, Nigam; Nair, Rashmi; Atreya, Hanudatta S; Gowda, Nagaraj; Ramachandra, Murali.

Afiliación

Sasikumar PG; Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India.
Sudarshan NS; Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India.
Adurthi S; Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India.
Ramachandra RK; Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India.
Samiulla DS; Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India.
Lakshminarasimhan A; Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India.
Ramanathan A; Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India.
Chandrasekhar T; Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India.
Dhudashiya AA; Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India.
Talapati SR; Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India.
Gowda N; Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India.
Palakolanu S; Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India.
Mani J; Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India.
Srinivasrao B; Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India.
Joseph D; NMR Research Centre, Indian Institute of Science, Bangalore, Karnataka, India.
Kumar N; Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India.
Nair R; Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India.
Atreya HS; NMR Research Centre, Indian Institute of Science, Bangalore, Karnataka, India.
Gowda N; Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India.
Ramachandra M; Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India. murali_r@aurigene.com.

Commun Biol ; 4(1): 699, 2021 06 08.

Article en En | MEDLINE | ID: mdl-34103659

Asunto(s)

Antineoplásicos/uso terapéutico; Neoplasias del Colon/tratamiento farmacológico; Inhibidores de Puntos de Control Inmunológico/uso terapéutico; Bibliotecas de Moléculas Pequeñas/uso terapéutico; Administración Oral; Animales; Antineoplásicos/administración & dosificación; Antineoplásicos/química; Línea Celular Tumoral; Descubrimiento de Drogas; Femenino; Humanos; Inhibidores de Puntos de Control Inmunológico/administración & dosificación; Inhibidores de Puntos de Control Inmunológico/química; Masculino; Ratones Endogámicos BALB C; Ratones Endogámicos C57BL; Receptor de Muerte Celular Programada 1/antagonistas & inhibidores; Bibliotecas de Moléculas Pequeñas/administración & dosificación; Bibliotecas de Moléculas Pequeñas/química

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias del Colon / Bibliotecas de Moléculas Pequeñas / Inhibidores de Puntos de Control Inmunológico / Antineoplásicos Límite: Animals / Female / Humans / Male Idioma: En Revista: Commun Biol Año: 2021 Tipo del documento: Article País de afiliación: India

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google